Cardiol Therapeutics Inc

TSX:CRDLCanadaView on NASDAQ

Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.

Contact Information

Headquarters

602-2265 Upper Middle Road EastOAKVILLE, ON, Canada L6H 0G5

Phone

289-910-0850

Fax

905-491-6793

Executives

Independent Chairman of the Board

Guillermo Torre-Amione

President, Chief Executive Officer, Director

David Elsley

Chief Financial Officer, Corporate Secretary, Director

Christopher Waddick

Chief Operating Officer

Bernard Lim

Chief Medical Officer, Head of Research and Development

Andrew Hamer